1. Home
  2. VCEL vs MLYS Comparison

VCEL vs MLYS Comparison

Compare VCEL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vericel Corporation

VCEL

Vericel Corporation

N/A

Current Price

$39.44

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$23.72

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VCEL
MLYS
Founded
1989
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
VCEL
MLYS
Price
$39.44
$23.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
10
Target Price
★ $60.57
$48.50
AVG Volume (30 Days)
397.9K
★ 1.2M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 60.00
37.43
EPS
★ N/A
N/A
Revenue
★ $276,259,000.00
N/A
Revenue This Year
$21.71
N/A
Revenue Next Year
$16.86
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 16.45
N/A
52 Week Low
$28.95
$22.30
52 Week High
$49.32
$47.65

Technical Indicators

Market Signals
Indicator
VCEL
MLYS
Relative Strength Index (RSI) 47.72 41.01
Support Level $37.78 $22.36
Resistance Level $41.12 $31.19
Average True Range (ATR) 1.17 1.37
MACD 0.26 -0.43
Stochastic Oscillator 69.65 15.65

Price Performance

Historical Comparison
VCEL
MLYS

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: